keyword
MENU ▼
Read by QxMD icon Read
search

lung adenocarcinoma brain metastases egfr

keyword
https://www.readbyqxmd.com/read/28717762/epidermal-growth-factor-receptor-mutational-status-and-brain-metastases-in-non-small-cell-lung-cancer
#1
Vijaya Raj Bhatt, Sanyo P D'Souza, Lynette M Smith, Allison M Cushman-Vokoun, Vanita Noronha, Vivek Verma, Amit Joshi, Anuradha Chougule, Nirmala Jambhekar, Anne Kessinger, Alissa Marr, Vijay Patil, Sripad D Banavali, Apar Kishor Ganti, Kumar Prabhash
INTRODUCTION: Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancers (NSCLC) may be more common in patients with brain metastases. Previous studies, however, did not adjust for effects of confounding variables. METHODS: This retrospective study included 1,522 consecutive patients with NSCLC, whose tumors were diagnosed and tested for EGFR mutations at the University of Nebraska Medical Center (Omaha, NE) and Tata Memorial Hospital (Mumbai, India)...
June 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28651600/validation-of-the-graded-prognostic-assessment-for-lung-cancer-with-brain-metastases-using-molecular-markers-lung-molgpa
#2
Carsten Nieder, Mandy Hintz, Oliver Oehlke, Angelika Bilger, Anca L Grosu
BACKGROUND: Many patients with brain metastases from non-small cell lung cancer have limited survival, while others survive for several years, depending on patterns of spread, EGFR and ALK alterations, among others. The purpose of this study was to validate a new prognostic model (Lung-molGPA) originally derived from a North American database. PATIENTS AND METHODS: This retrospective study included 269 German and Norwegian patients treated with individualized approaches, always including brain radiotherapy...
June 26, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28597503/prognostic-model-for-brain-metastases-from-lung-adenocarcinoma-identified-with-epidermal-growth-factor-receptor-mutation-status
#3
Hongwei Li, Weili Wang, Haixia Jia, Jianhong Lian, Jianzhong Cao, Xiaqin Zhang, Xing Song, Sufang Jia, Zhengran Li, Xing Cao, Wei Zhou, Songye Han, Weihua Yang, Yanfen Xi, Shenming Lian
BACKGROUND: Several indices have been developed to predict survival of brain metastases (BM) based on prognostic factors. However, such models were designed for general brain metastases from different kinds of cancers, and prognostic factors vary between cancers and histological subtypes. Recently, studies have indicated that epidermal growth factor receptor (EGFR) mutation status may be a potential prognostic biological factor in BM from lung adenocarcinoma. Thus, we sought to define the role of EGFR mutation in prognoses and introduce a prognostic model specific for BM from lung adenocarcinoma...
June 9, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28540256/concurrent-afatinib-and-whole-brain-radiotherapy-in-exon-19-del-egfr-mutant-lung-adenocarcinoma-a-case-report-and-mini-review-of-the-literature
#4
Chukwuka Eze, Nina-Sophie Hegemann, Olarn Roengvoraphoj, Maurice Dantes, Farkhad Manapov
Leptomeningeal metastases (LM) are found in approximately 3.8% of non-small cell lung cancer cases with an increased incidence in adenocarcinoma, and approximately one-third of patients will present with concomitant brain metastases. We report the case of a 50-year-old male patient with stage IV exon 19-del-EGFR mutant lung adenocarcinoma who progressed on second-generation TKI therapy with manifestation of symptomatic simultaneous diffuse brain and LM. Whole-brain radiotherapy with concurrent afatinib resulted in an almost complete regression of neurological symptoms as well as good, durable radiological response...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28413660/dramatic-intracranial-response-to-osimertinib-in-a-poor-performance-status-patient-with-lung-adenocarcinoma-harboring-the-epidermal-growth-factor-receptor-t790m-mutation-a-case-report
#5
Takehiro Uemura, Tetsuya Oguri, Minami Okayama, Hiromi Furuta, Yoshihiro Kanemitsu, Osamu Takakuwa, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito, Akio Niimi
We herein report a case of dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor (EGFR) T790M mutation encoded in exon 20. The patient was a 59-year-old woman with EGFR exon 19 deletion-positive lung adenocarcinoma, who relapsed with multiple brain metastases. Computed tomography-guided biopsy of the left pleural tumor revealed adenocarcinoma harboring an EGFR exon 19 deletion and an EGFR T790M mutation encoded in exon 20...
April 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28412028/-effectiveness-of-erlotinib-in-critical-care-unit-in-patients-with-non-small-cell-lung-cancer-with-egfr-mutation
#6
M Dewolf, C Dayen, C Garoute, W Khamis, M Fourrier, F Rousselle, M Sadki, F Le Meunier, R Suguenot, E Lecuyer, H Bentayeb, Y Douadi, P Berna
INTRODUCTION: The search for mutations epidermal growth factor receptor (EGFR) has changed the therapeutic approach and prognosis of non-small cell lung cancer (NSCLC). The effectiveness of tyrosine kinase inhibitors (TKI) has been demonstrated orally in patients with EGFR mutation. We report the case of a patient for whom treatment with TKI was started effectively in a Critical Care Unit. OBSERVATION: A patient of 59 years is followed for a stage IV lung adenocarcinoma with metastases in liver, brain, adrenal, lung and pleura...
June 2017: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/28391386/assessment-of-prognostic-scores-of-brain-metastases-from-lung-adenocarcinoma-with-egfr-mutations
#7
Hongwei Li, Jianhong Lian, Hongxing Jin, Weili Wang, Jianzhong Cao, Xiaqin Zhang, Xin Song, Sufang Jia, Haixia Jia, Jiwei Ren, Songyan Han, Weihua Yang, Yanfeng Xi, Shengmin Lan
The aim of this study was to analyze prognostic factors and evaluate the value of four prognostic scores including RPA, DS-GPA BS-BM, GGS for the EGFR mutant BM patients from lung adenocarcinoma treated with EGFR-TKI. Data of NSCLC were retrospectively reviewed from August 2010 to June 2015 using the medical database of Shanxi Provincial Cancer Hospital. Patients with BM from lung adenocarcinoma with mutant EGFR treated by EGFR-TKI or a combination of EGFR-TKI and WBRT were included. Potential prognostic factors were statistically examined...
April 8, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28332624/effects-of-icotinib-with-and-without-radiation-therapy-on-patients-with-egfr-mutant-non-small-cell-lung-cancer-and-brain-metastases
#8
Yun Fan, Yanjun Xu, Lei Gong, Luo Fang, Hongyang Lu, Jing Qin, Na Han, Fajun Xie, Guoqin Qiu, Zhiyu Huang
EGFR-TKIs and radiation therapy (RT) are the principal treatment for patients with brain metastases (BM) and EGFR mutant NSCLC. However, the optimal use of brain RT for patients with asymptomatic BM remains undefined. A total of 152 patients were identified. 58 patients were excluded. Of the remaining 97 patients, 56 patients received upfront RT followed by icotinib, including WBRT or SRS. 41 patients received icotinib therapy alone. The mOS from diagnosis of BM was 27.0 months for the whole cohort (95% CI, 23...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28254368/the-impact-of-tumor-biology-on-survival-and-response-to-radiation-therapy-among-patients-with-non-small-cell-lung-cancer-brain-metastases
#9
Jacob A Miller, Rupesh Kotecha, Manmeet S Ahluwalia, Alireza M Mohammadi, John H Suh, Gene H Barnett, Erin S Murphy, Michael A Vogelbaum, Lilyana Angelov, Samuel T Chao
PURPOSE: To investigate the natural history and response to radiation therapy among ALK-rearranged, EGFR-mutated, wild-type adenocarcinoma, and squamous cell non-small cell lung cancer (NSCLC) brain metastases. METHODS AND MATERIALS: Patients with NSCLC brain metastasis diagnosed from 1989 through 2014 at a single tertiary-care institution were included. The primary outcome was overall survival, whereas secondary outcomes included local failure, distant intracranial failure, and radiation necrosis...
January 5, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28228223/-clinical-experience-with-first-generation-epidermal-growth-factor-receptor-%C3%A2-tyrosine-kinase-inhibitors-in-non-small-cell-lung-cancer-patients-%C3%A2-with-brain-metastasis
#10
Huixing Dong, Shaohua Cui, Feng Pan, Lili Dong, Yanjie Niu, Yizhuo Zhao, Aiqin Gu, Xiaoyan Jin, Liyan Jiang
BACKGROUND: A survival analysis and the influencing factors for non-small cell lung cancer (NSCLC) patients with brain metastases accepting first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) treatment have not yet been elucidated to date. In this study, we collected and analyzed the survival data of NSCLC patients with brain metastasis to obtain evidence and to provide guidance in clinical practice. METHODS: NSCLC patients with brain metastases who were treated with first-generation EGFR-TKIs were retrospectively collected in 2012-2013 from Shanghai Chest Hospital, Shanghai Jiao Tong University...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28056322/-the-therapeutic-value-and-safety-of-icotinib-as-first-line-therapy-for-advanced-non-small-cell-lung-cancer-patients
#11
H Chen, H P Wang, L Zhang, X Y Si
Objective: To evaluate the safety and efficacy of icotinib as first-line therapy in Chinese non-small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) sensitive mutations. Methods: Patients with stage ⅢB/Ⅳ NSCLC who had EGFR sensitive mutation and had no previous treatment were enrolled into this study. The response rates, progress free survival (PFS), overall survival (OS), and the safety were analyzed. Results: Ninety advanced adenocarcinoma patients were enrolled in this study, 44 patients had partial response (PR), 42 patients had stable disease (SD), 4 patients had progressive disease (PD), with an overall response rate (ORR) of 48...
January 1, 2017: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/28051122/kras-mutation-incidence-and-prognostic-value-are-metastatic-site-specific-in-lung-adenocarcinoma-poor-prognosis-in-patients-with-kras-mutation-and-bone-metastasis
#12
Zoltan Lohinai, Thomas Klikovits, Judit Moldvay, Gyula Ostoros, Erzsebet Raso, Jozsef Timar, Katalin Fabian, Ilona Kovalszky, István Kenessey, Clemens Aigner, Ferenc Renyi-Vamos, Walter Klepetko, Balazs Dome, Balazs Hegedus
Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC). We investigated the effect of KRAS mutation on overall survival (OS) in this setting. In our retrospective study, 500 consecutive Caucasian metastatic LADC patients with known KRAS mutational status were analyzed after excluding 32 patients with EGFR mutations. KRAS mutation incidence was 28.6%. The most frequent metastatic sites were lung (45.6%), bone (26.2%), adrenal gland (17...
January 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/27892978/estimating-survival-in-patients-with-lung-cancer-and-brain-metastases-an-update-of-the-graded-prognostic-assessment-for-lung-cancer-using-molecular-markers-lung-molgpa
#13
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
Importance: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. Objective: To update the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases...
June 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/27888377/correlation-between-status-of-epidermal-growth-factor-receptor-mutation-and-distant-metastases-of-lung-adenocarcinoma-upon-initial-diagnosis-based-on-1063-patients-in-china
#14
Hongwei Li, Jianzhong Cao, Xiaqin Zhang, Xing Song, Weili Wang, Sufang Jia, Zhengran Li, Haixia Jia, Xing Cao, Wei Zhou, Jianhong Lian, Songye Han, Weihua Yang, Yanfen Xi, Shenming Lian, Haoxing Jing
The study aimed to explore the correlations between status of epidermal growth factor receptor (EGFR) mutations and distant metastases. A total of 1063 patients with lung adenocarcinoma indentified with status of EGFR mutations from August 2010 to May 2015 at Shanxi Cancer Hospital were enrolled. 456 patients were confirmed with EGFR mutations. The associations among EGFR mutations, clinical factors, and distant metastases at initial diagnosis were evaluated. Patients harboring EGFR mutation were more likely to be female (P < 0...
January 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/27675604/comparing-the-clinical-efficacy-of-tki-alone-with-tki-plus-concomitant-wbrt-for-egfr-mutation-positive-lung-adenocarcinoma-patients-with-brain-metastases-a-retrospective-study
#15
H Ge, Q Zhu, Y Sun
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27627582/first-line-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitor-alone-or-with-whole-brain-radiotherapy-for-brain-metastases-in-patients-with-egfr-mutated-lung-adenocarcinoma
#16
Yongshun Chen, Jing Yang, Xue Li, Daxuan Hao, Xiaoyuan Wu, Yuanyuan Yang, Chunyu He, Wen Wang, Jianhua Wang
We proposed to compare the outcomes of first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone with EGFR-TKI plus whole-brain radiotherapy (WBRT) for the treatment of brain metastases (BM) in patients with EGFR-mutated lung adenocarcinoma. A total of 1665 patients were screened from 2008 to 2014, and 132 were enrolled in our study. Among the 132 patients, 72 (54.5%) harbored a deletion in exon 19, 97 (73.5%) showed multiple intracranial lesions, and 67 (50.8%) had asymptomatic BM...
December 2016: Cancer Science
https://www.readbyqxmd.com/read/27598807/the-effect-of-gene-alterations-and-tyrosine-kinase-inhibition-on-survival-and-cause-of-death-in-patients-with-adenocarcinoma-of-the-lung-and-brain-metastases
#17
MULTICENTER STUDY
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
PURPOSE: Lung cancer remains the most common cause of both cancer mortality and brain metastases (BM). The purpose of this study was to assess the effect of gene alterations and tyrosine kinase inhibition (TKI) on median survival (MS) and cause of death (CoD) in patients with BM from lung adenocarcinoma (L-adeno). METHODS: A multi-institutional retrospective database of patients with L-adeno and newly diagnosed BM between 2006 and 2014 was created. Demographics, gene alterations, treatment, MS, and CoD were analyzed...
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27561804/-analysis-of-clinicopathological-feature-and-prognosis-for-%C3%A2-leptomeningeal-metastasis-in-non-small-cell-lung-cancer
#18
Min Zhu, Yanhong Ren, Yan Liu, Chengjun Ban, Hua Gu, Zheng Wang, Yuhui Zhang
BACKGROUND: Leptomeningeal metastases (LM) is one of the most serious complications of advanced non-small cell lung cancer (NSCLC) due to the lower quality of life and poor prognosis. The aim of this study is to analyze the clinicopathological features and prognosis of patients with LM from NSCLC (NSCLC-LM). METHODS: Clinical data of 3 patients with NSCLC-LM collected from January 2015 to June 2016 were analyzed with a brief review. RESULTS: All 3 patients had adenocarcinoma histology harboring epidermal growth factor receptor (EGFR) exon 21 point mutations (m)...
August 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27486770/a-retrospective-analysis-in-patients-with-egfr-mutant-lung-adenocarcinoma-is-egfr-mutation-associated-with-a-higher-incidence-of-brain-metastasis
#19
Guang Han, Jianping Bi, Wenyong Tan, Xueyan Wei, Xiaohong Wang, Xiaofang Ying, Xiaofang Guo, Xiaoyi Zhou, Desheng Hu, Weining Zhen
Lung adenocarcinomas are more commonly associated with brain metastases (BM). Epidermal growth factor receptor (EGFR) mutations have been demonstrated to be both predictive and prognostic for patients with lung adenocarcinoma. We aimed to explore the potential association between EGFR mutation and the risk of BM in pulmonary adenocarcinoma patients. Data of 234 patients from 2007 to 2014 were retrospectively reviewed. A total of 108 patients had EGFR mutations in the entire cohort. Among them, 76 patients developed BM during their disease course...
August 30, 2016: Oncotarget
https://www.readbyqxmd.com/read/27446584/quick-regression-of-brain-metastases-from-lung-adenocarcinoma-with-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-treatment-a-case-report-and-literature-review
#20
Huaqiong Huang, Shuangli Zhu, Shaobin Wang, Wen Li
Brain metastasis (BM) commonly occurs in patients with advanced lung cancer, and is associated with poor prognosis and limited treatment options, particularly for end-stage patients who are in poor physical and mental state. We herein present a case of lung adenocarcinoma with BM, as revealed by tumor marker and imaging studies. The patient was a 74-year-old woman who was diagnosed with lung adenocarcinoma with several metastatic lesions in the mediastinal lymph nodes, bone and brain. The patient underwent two cycles of chemotherapy, but the cancer recurred with enlarged BM, resulting in confusion and body dysfunction...
August 2016: Molecular and Clinical Oncology
keyword
keyword
98956
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"